
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is a promising medical technology company with a focused strategy on developing and commercializing innovative diagnostic testing products for complex autoimmune diseases. Their recent financial results show strong revenue growth and improvement in volume and ASPs, and management has reaffirmed their revenue guidance for 2026. Despite facing potential risks such as reimbursement and payor concentration, Exagen's unique position in the market and potential for future product development make it a strong investment opportunity.
Bears say
Exagen is a small biopharma and medical technology company with a growing pharma service offering. However, the loss of a direct bill account and lower reimbursement rates could impact growth and profitability. The company is also facing competition from larger players and reimbursement risks. While the company's recent financial results have been positive, the uncertainty around future growth and profits warrants a negative outlook.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares